Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
N-Acetylaspartate (NAA) is the second most abundant organic metabolite in the brain, but its physiological significance remains enigmatic. Toxic NAA accumulation appears to be the key factor for neurological decline in Canavan disease-a fatal neurometabolic disorder caused by deficiency in the NAA-degrading enzyme aspartoacylase. To date clinical outcome of gene replacement therapy for this spongiform leukodystrophy has not met expectations. To identify the target tissue and cells for maximum anticipated treatment benefit, we employed comprehensive phenotyping of novel mouse models to assess cell type-specific consequences of NAA depletion or elevation. We show that NAA-deficiency causes neurological deficits affecting unconscious defensive reactions aimed at protecting the body from external threat. This finding suggests, while NAA reduction is pivotal to treat Canavan disease, abrogating NAA synthesis should be avoided. At the other end of the spectrum, while predicting pathological severity in Canavan disease mice, increased brain NAA levels are not neurotoxic per se. In fact, in transgenic mice overexpressing the NAA synthesising enzyme Nat8l in neurons, supra-physiological NAA levels were uncoupled from neurological deficits. In contrast, elimination of aspartoacylase expression exclusively in oligodendrocytes elicited Canavan disease like pathology. Although conditional aspartoacylase deletion in oligodendrocytes abolished expression in the entire CNS, the remaining aspartoacylase in peripheral organs was sufficient to lower NAA levels, delay disease onset and ameliorate histopathology. However, comparable endpoints of the conditional and complete aspartoacylase knockout indicate that optimal Canavan disease gene replacement therapies should restore aspartoacylase expression in oligodendrocytes. On the basis of these findings we executed an ASPA gene replacement therapy targeting oligodendrocytes in Canavan disease mice resulting in reversal of pre-existing CNS pathology and lasting neurological benefits. This finding signifies the first successful post-symptomatic treatment of a white matter disorder using an adeno-associated virus vector tailored towards oligodendroglial-restricted transgene expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koch, M. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00098-7 · Cited by 1,287 · cited 9×
“Imbalances of GABAergic and glycinergic neurotransmission in axons of giant neurons of the pontine reticular formation, as well as loss of these cells have been associated with impaired ASR [41], and NMDA receptor activity is critical for a normal ASR response [37].”
InfluentialDisruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination
Lappe-Siefke, C., Goebbels, S., Gravel, M., Nicksch, E., Lee, J., Braun, P. E., Griffiths, I. R., & Nave, K.-A. (2003) · Nature Genetics · doi:10.1038/ng1095 · Cited by 1,036 · cited 1×
“Crossing with CnpCre/+ mice [45] disrupted the Aspaflox/flox allele within cells of the oligodendrocyte lineage (Aspa∆OL).”
The movers and shapers in immune privilege of the CNS
Engelhardt, B., Vajkoczy, P., & Weller, R. O. (2017) · Nature Immunology · doi:10.1038/ni.3666 · Cited by 893 · cited 1×
“The CNS is widely recognized as an immune privileged organ as it largely lacks a potent innate immune response [20].”
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 1×
“Nevertheless, immunogenicity and limitations in production continue to impede systemic AAV delivery for treatment of CNS disorders in humans [42].”
Long-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
Oligodendroglial myelination requires astrocyte-derived lipids
Camargo, N., Goudriaan, A., van Deijk, A.-L. F., Otte, W. M., Brouwers, J. F., Lodder, H., Gutmann, D. H., Nave, K.-A., Dijkhuizen, R. M., Mansvelder, H. D., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.1002605 · Cited by 296
Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease
Kaul, R., Ping Gao, G., Balamurugan, K., & Matalon, R. (1993) · Nature Genetics · doi:10.1038/ng1093-118 · Cited by 221 · cited 1×
“CD is a fatal neurodegenerative disorder, where patients fail to reach developmental milestones, and presents with macrocephaly, seizures, widespread CNS vacuolization and hypomyelination [38, 49].”
Karlsson, R.-M., Tanaka, K., Saksida, L. M., Bussey, T. J., Heilig, M., & Holmes, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.215 · Cited by 165 · cited 1×
“Imbalances of GABAergic and glycinergic neurotransmission in axons of giant neurons of the pontine reticular formation, as well as loss of these cells have been associated with impaired ASR [41], and NMDA receptor activity is critical for a normal ASR response [37].”
Glial promoter selectivity following AAV-delivery to the immature brain
von Jonquieres, G., Mersmann, N., Klugmann, C. B., Harasta, A. E., Lutz, B., Teahan, O., Housley, G. D., Fröhlich, D., Krämer-Albers, E.-M., & Klugmann, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065646 · Cited by 133
Self-citationSchoenfeld, R., Wong, A., Silva, J., Li, M., Itoh, A., Horiuchi, M., Itoh, T., Pleasure, D., & Cortopassi, G. (2010) · Mitochondrion · doi:10.1016/j.mito.2009.12.141 · Cited by 112 · cited 1×
“This indicates that NAA, while likely to contribute to osmoregulation, myelination, energy and pH homeostasis in the brain [56, 66, 68, 77], is not essential for these processes.”
Pessentheiner, A. R., Pelzmann, H. J., Walenta, E., Schweiger, M., Groschner, L. N., Graier, W. F., Kolb, D., Uno, K., Miyazaki, T., Nitta, A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491324 · Cited by 105 · cited 1×
“1 3 attributed to lipid turnover and energy expenditure [57], we investigated the effects of genetic NAA imbalances on whole body composition (Fig.”
Gessler, D. J., Li, D., Xu, H., Su, Q., Sanmiguel, J., Tuncer, S., Moore, C., King, J., Matalon, R., & Gao, G. (2017) · JCI Insight · doi:10.1172/jci.insight.90807 · Cited by 70
von Jonquieres, G., Fröhlich, D., Klugmann, C. B., Wen, X., Harasta, A. E., Ramkumar, R., Spencer, Z. H. T., Housley, G. D., & Klugmann, M. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00013 · Cited by 61 · cited 3×
“Packaging, purification and titering of AAV vectors (serotype cy5), was performed as described previously [19, 78].”
MethodSelf-citationKlugmann, M., Leichtlein, C. B., Symes, C. W., Serikawa, T., Young, D., & During, M. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.006 · Cited by 55 · cited 1×
“In line with this hypothesis direct intracranial AAV-ASPA gene delivery to CNS neurons showed limited therapeutic benefit [2, 3, 40], while in a recent study neonatal delivery of a novel AAV serotype that preferably infects oligodendrocytes prevented development of CD in ASPAnur7/nur7 mice, at least until three months…”
Self-citationAblating N‐acetylaspartate prevents leukodystrophy in a Canavan disease model
Guo, F., Bannerman, P., Mills Ko, E., Miers, L., Xu, J., Burns, T., Li, S., Freeman, E., McDonough, J. A., & Pleasure, D. (2015) · Annals of Neurology · doi:10.1002/ana.24392 · Cited by 52 · cited 3×
“Utilizing alternative models, we confirm that key aspects of the pathology are paralleled by dose-dependent NAA toxicity and that NAA depletion prevents CD [32, 51].”
Francis, J. S., Wojtas, I., Markov, V., Gray, S. J., McCown, T. J., Samulski, R. J., Bilaniuk, L. T., Wang, D.-J., De Vivo, D. C., Janson, C. G., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.10.001 · Cited by 49
Aspartoacylase supports oxidative energy metabolism during myelination
Francis, J. S., Strande, L., Markov, V., & Leone, P. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.66 · Cited by 41
Ahmed, S. S., Schattgen, S. A., Frakes, A. E., Sikoglu, E. M., Su, Q., Li, J., Hampton, T. G., Denninger, A. R., Kirschner, D. A., Kaspar, B., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.68 · Cited by 24
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“New technologies using AAV-ASPA targeting oligodendrocytes are now being studied.(57)”
MethodAAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Oligodendroglial Energy Metabolism and (re)Myelination
Tepavčević, V. (2021) · Life · doi:10.3390/life11030238 · Cited by 57
“into hypomyelination, and decreased galactosylceramide amounts in brain homogenates[85].”
BackgroundFrancis, J. S., Markov, V., Wojtas, I. D., Gray, S., McCown, T., Samulski, R. J., Figueroa, M., & Leone, P. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.009 · Cited by 41
Metadata
- Authors
- von Jonquieres, G., Spencer, Z. H. T., Rowlands, B. D., Klugmann, C. B., Bongers, A., Harasta, A. E., Parley, K. E., Cederholm, J., Teahan, O., Pickford, R., Delerue, F., Ittner, L. M., Fröhlich, D., McLean, C. A., Don, A. S., Schneider, M., Housley, G. D., Rae, C. D., & Klugmann, M.
- Venue
- Acta Neuropathologica
- Published
- 2017-11-07
- Volume
- 135
- Issue
- 1
- Pages
- 95-113
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2767544358
- Cited by
- 57
- References
- 19
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.